Search the Newsreel

RIGL Maintained by HC Wainwright & Co. -- Price Target Raised to $85

HC Wainwright & Co. maintained a "Buy" rating for Rigel Pharmaceuticals (RIGL), increasing its price target from $57.00 to $85.00, reflecting confidence in the company's future growth. Despite this, Rigel Pharmaceuticals is currently priced at $42.10, which is 56.7% overvalued compared to its GF …

Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer

Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant) in the United States. This drug is the first and only FDA-approved PROTAC and is indicated for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have progressed after at least one line …

Rigel Pharmaceuticals (RIGL): Soleus Capital group discloses 9.9% ownership stake

Soleus Capital Master Fund, L.P. and its affiliated entities have reported a 9.9% beneficial ownership stake in Rigel Pharmaceuticals, Inc. (RIGL). This ownership amounts to 1,843,504 shares of common stock, based on 18,679,864 shares outstanding as of July 30, 2026. The filing indicates shared …

Rigel's VEPPANU Is Now Available for Certain Advanced Breast Cancers

Rigel Pharmaceuticals has announced the commercial availability of VEPPANU (vepdegestrant), an FDA-approved oral PROTAC, in the United States and Puerto Rico. This new treatment is for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line …

Rigel (RIGL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Raul RodriguezChief Commercial Officer - David SantosChief Financial Officer - Dean SchornoChief Medical Officer - Alison Hannah Need a quote from a …

Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates

Rigel Pharmaceuticals, Inc. $RIGL Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP significantly increased its stake in Rigel Pharmaceuticals (NASDAQ:RIGL) by 37.1% in the first quarter, now owning 379,541 shares valued at $10.3 million. This contributed to institutional investors holding 66.23% of the stock. Despite a "Strong Sell" downgrade from Zacks Research, …

HC Wainwright Issues Pessimistic Estimate for RIGL Earnings

H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57

H.C. Wainwright has reiterated its Buy rating for Rigel Pharmaceuticals (RIGL.US), maintaining a target price of $57. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

Rigel Pharmaceuticals (RIGL) Stock Rally Runs Into Earnings Quality Doubts

Rigel Pharmaceuticals (RIGL) saw its stock rally after its Q2 earnings release, with a 4.6% increase following a strong three-month run. The company maintained profitability with $17.3m in net income and $78.7m in total revenue, though revenue and EPS declined significantly year-over-year. While the …

Rigel Pharmaceuticals: The Easy Money Has Been Made (Rating Downgrade)

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up on Earnings Beat

Is Rigel Pharmaceuticals (RIGL) Overvalued After Q2 Earnings Bea

Rigel Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RIGL)

Rigel Pharmaceuticals, Inc. (RIGL) published a slide deck in conjunction with their Q2 2026 earnings call. The company reported an EPS of $0.88, beating estimates by $0.96, and revenue of $78.70M, which also beat estimates by $23.43M despite a 22.60% year-over-year decrease. This article …

Rigel Pharmaceuticals (NASDAQ:RIGL) Posts Earnings Results, Beats Estimates By $0.79 EPS

Rigel Pharmaceuticals (RIGL) reported Q2 earnings of $0.88 per share, missing the Zacks Consensus Estimate of $0.91 per share, and significantly down from $3.28 per share a year ago. Despite missing EPS estimates, the company's Q2 revenues of $78.7 million surpassed the consensus estimate …

(RIGL) as a Liquidity Pulse for Institutional Tactics

This article analyzes Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) using AI models, highlighting weak near and mid-term sentiment but a neutral long-term outlook. It identifies an exceptional short setup with a significant risk-reward ratio and outlines specific trading strategies for different risk profiles. The analysis …

Rigel Pharmaceuticals (RIGL) Earnings Date and Reports 2026 $RIGL

Rigel Pharmaceuticals Inc (RIGL) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Rigel Pharmaceuticals Inc (RIGL), noting its current risk score of 4.47 and ranking it 86th out of 155 in the Pharmaceuticals industry. It highlights the company's beta of 1.19, indicating higher volatility compared to the S&P 500 …

Earnings Preview: RIGL to Report Financial Results Post-market on August 04

This article announces that Rigel Pharmaceuticals (RIGL) is scheduled to release its financial results after market close on August 4. The company will also host a webcast and conference call at 4:30 PM ET to discuss these results, which will be accessible for replay.

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the …

Rigel Pharmaceuticals Inc (RIGL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rigel Pharmaceuticals Inc (RIGL), highlighting its current valuation score and P/E ratio. It notes that the company's P/E ratio is 1.90, significantly below its recent high and above its recent low. The analysis also indicates that relevant …

Rigel schedules a live webcast for its Aug. 4 business update

Rigel Pharmaceuticals (Nasdaq: RIGL) announced it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after market close. A live conference call and webcast will follow at 4:30 p.m. ET, led by senior management, to discuss the results and provide …

Rigel Pharmaceuticals (RIGL) Projected to Announce Earnings on Tuesday

RIGL|Rigel Pharmaceuticals Inc|Price:37.126|Chg%:-0.264

This article provides a comprehensive stock analysis of Rigel Pharmaceuticals Inc (RIGL) by TradingKey. It highlights the company's strong fundamentals and high growth potential, despite its stock trading sideways recently. The analysis also covers the company's valuation, institutional ownership, and analyst ratings, indicating a …

Rigel Pharmaceuticals Inc (RIGL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Rigel Pharmaceuticals Inc (RIGL), highlighting major institutional investors and their holdings. It breaks down shareholders by type and reports on changes in institutional ownership over several quarters. The data provides insights into which firms have significant stakes …

Rigel Pharmaceuticals Inc (RIGL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical data on dividends and stock splits for Rigel Pharmaceuticals Inc (RIGL). It indicates that the company has not distributed any dividends in the past five years. The report also details multiple merger-related stock splits with a 10:1 ratio that occurred …

Rigel Pharmaceuticals Inc (RIGL) Income Statement

This article provides the quarterly and annual income statements for Rigel Pharmaceuticals Inc (RIGL), offering detailed financial data such as total revenue, cost of revenue, operating expenses, and net income across multiple fiscal years and quarters. It also includes frequently asked questions about interpreting …

Rigel Pharmaceuticals, Inc. Revenue Breakdown – MUN:RI2

Rigel Pharmaceuticals, Inc. (MUN:RI2) generated 250.56 million EUR last year, a significant increase from 173.18 million EUR in the previous year. This revenue primarily stemmed from its Novel Therapies segment, with the United States being the largest contributing region. The company's financial performance highlights …

Rigel Pharmaceuticals Inc (RIGL) Financial Health: Profitability & Balance Sheet Analysis

Rigel Pharmaceuticals Inc (RIGL) has a robust financial health score of 8.03, ranking 86th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company reported a 10.28% year-over-year revenue increase to $58.82 million and a 24.39% year-over-year increase in net profit. …

(RIGL) Risk Channels and Responsive Allocation

Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is presenting a weak near-term sentiment, although an exceptional 81.5:1 risk-reward setup is noted, targeting a 24.2% gain against 0.3% risk. AI models have developed three trading strategies: Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT), each …

RIGL Forecast — Price Target — Prediction for 2027

Price to earnings forward of Rigel Pharmaceuticals, Inc. – NASDAQ:RIGL

A Look At The Transformation Around Rigel Pharmaceuticals (NASDAQ:RIGL)